Abstracts tagged "rheumatoid arthritis (RA) and tumor necrosis factor (TNF)"

Abstract Number: 1322 • 2013 ACR/ARHP Annual Meeting
Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Rachel Audo¹, Laura Papon¹, Claire I. Daien^1,2, Cédric Lukas³, Bernard Combe², Olivier Vittecoq⁴, Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear factor…
Abstract Number: 1000 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection
An Tran-Duy¹, Annelies Boonen², Wietske Kievit³, Piet L.C.M. van Riel⁴, Mart A.F.J. van de Laar⁵ and Johan L. Severens⁶, ¹Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ⁶Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands
Background/Purpose: In clinical practice, management of rheumatoid arthritis (RA) is characterized by a sequence of drugs which is determined based on patient characteristics, notably disease…
Abstract Number: 804 • 2013 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitors and The Risk Of Acute Coronary Syndrome In Rheumatoid Arthritis – a National Cohort Study
Lotta Ljung^1,2, Johan Askling³, Solbritt M. Rantapää-Dahlqvist⁴, Lennart T.H. Jacobsson⁵ and The ARTIS Study Group⁶, ¹Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The high risk of ischemic heart disease (IHD) in patients with rheumatoid arthritis (RA) has been linked to inflammation and disease severity. Treatment with…
Abstract Number: 805 • 2013 ACR/ARHP Annual Meeting
Good Response On Tumour Necrosis Factor Inhibitors Are Associated With a Decreased Risk Of Acute Coronary Syndromes In Patients With Rheumatoid Arthritis
Lotta Ljung^1,2, Lennart T.H. Jacobsson³, Solbritt M. Rantapää-Dahlqvist⁴, Johan Askling⁵ and The ARTIS Study Group⁶, ¹Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁴Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Inflammatory activity, as well as traditional cardiovascular risk factors, have been suggested to underlie the increased risk of coronary disease in patients with rheumatoid…
Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting
COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys
Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…
Abstract Number: 2466 • 2012 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project
Christina D. Chambers¹, Diana L. Johnson², Yunjun Luo¹, Janina L. Jimenez¹, Nicole Mirrasoul¹, Elizabeth Salas¹, Kenneth Lyons Jones² and OTIS Research Group³, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Pediatrics, La Jolla
Background/Purpose: The fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab (ADA), is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile…
Abstract Number: 1992 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Allen P. Anandarajah¹, Jennifer Hossler², Kate Burns³, Kelly Callahan³, Yahui Grace Chiu³ and Jennifer H. Anolik⁴, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Rheumatology, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Generalized bone loss (osteoporosis or osteopenia) is more common in patients with rheumatoid arthritis (RA) than in the general population. Recent studies suggest that…
Abstract Number: 1783 • 2012 ACR/ARHP Annual Meeting
TNFα Influences RasGRP1 and RasGRP3 Expression Levels in PBMC, B and T Cells
Marie-Laure Potier¹, Martine Hiron¹, Clément Guillou¹, Céline Derambure², Olivier Boyer³, Xavier Le Loët⁴, Olivier Vittecoq⁵ and Thierry Lequerré⁶, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, Inserm 905, Institute for Biomedical research, University of Rouen, Rouen, France, ⁴Rheumatology Department, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁶Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T lymphocytes play a central role in the pathophysiology of RA. RasGRP is…
Abstract Number: 1789 • 2012 ACR/ARHP Annual Meeting
Evidence for an Additive Effect of Tumor Necrosis Factor Alpha and Hypoxia to Promote Bone Destruction in Arthritis
Shankar Revu¹, Akilan Krishnamurthy², Vivekananda Sunkari³, Ileana R. Botusan³, Xiaowei Zheng³, Sergiu-Bogdan Catrina⁴ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Hypoxia is a major feature of the inflamed rheumatoid arthritis synovial membrane and promotes osteoclasts formation in vitro. We aimed to investigate the molecular…
Abstract Number: 1593 • 2012 ACR/ARHP Annual Meeting
The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Louise K. Mercer¹, Mark Lunt², Audrey S. Low³, James B. Galloway², Kath Watson⁴, William G. Dixon⁵, BSRBR Control Centre Consortium², Deborah P. Symmons³, Kimme L. Hyrich⁶ and On behalf of the BSRBR⁷, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵The University of Manchester, Manchester, United Kingdom, ⁶Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose: The risk of lymphoma is increased in people with RA compared to the general population and is greatest in severe RA. Anti-TNF therapy is…
Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Masahiro Sekiguchi¹, Kiyoshi Matsui¹, Masayasu Kitano¹, Mitsuo Namiki¹, Koichiro Ohmura², Takao Fujii³, Hideko Nakahara⁴, Keiji Maeda⁴, Hideo Hashimoto⁵, Takanori Kuroiwa⁶, Kenji Miki⁷, Masanori Funauchi⁸, Kazuhiro Hatta⁹, Kenshi Higami¹⁰, Shunzo Namiuchi¹¹, Ichiro Yoshii¹², Teruyuki Nakatani¹³, Takashi Ikawa¹⁴, Takaji Matsutani¹⁵, Kosaku Murakami¹⁶, Satoshi Morita¹⁷, Yutaka Kawahito¹⁸, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁹ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Department of Rheumatology & Clin Immunology, Kyoto University, Kyoto, Japan, ³Dept of Rheum/Clinical Immun, Graduate School of Medicine,, Kyoto University, Kyoto, Japan, ⁴Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁵Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁶Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁸Division of Hematology and Rheumatology, Department of Medicine, Kinki University Faculty of Medicine, Osaka, Japan, ⁹Department of Internal Medicine, Tenri Yorozu Sodansyo Hospital, Nara, ¹⁰Department of Rheumatology, Higami Hospital, Nara, Japan, ¹¹Department of Rheumatology, Saiseikai Nakatsu Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Department of Orthopaedic Surgery, Kishiwada City Hospital, Osaka, Japan, ¹⁴Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁵Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ¹⁶Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁷Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁸Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁹Dept of Rheum & Clinical Immun, Kyoto University, Kyoto, Japan
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…
Abstract Number: 1207 • 2012 ACR/ARHP Annual Meeting
Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells
Ezinma Ezealah¹, Jennifer Hossler¹, Jamie Biear¹, Christopher A. Cistrone¹, Teresa Owen¹, Nida Meednu¹, Kelly Callahan¹, Arumugam Palanichamy¹, Ignacio Sanz², Allen P. Anandarajah¹, Ralf G. Thiele¹, Darren Tabechian³, R. John Looney¹ and Jennifer H. Anolik¹, ¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Rheumatology, Emory University, Atlanta, GA, ³Allergy/Immun/Rheumatology, Univ of Rochester Schl of Med, Rochester, NY
Background/Purpose: Serum receptor activator of NFkB ligand (RANKL) and its natural decoy receptor, osteoprotegerin (OPG), play key roles in osteoclast activation. In a group of…
Abstract Number: 468 • 2012 ACR/ARHP Annual Meeting
Adalimumab Treatment Is Associated with Decreased Concomitant Rheumatoid Arthritis Medication Use Over 24 Months
Daniel Furst¹, Neelufar Mozaffarian², Shannon Grant³, Mary Cifaldi², Jerry Clewell², Joel M. Kremer⁴ and James Shaw⁵, ¹Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ²Abbott Laboratories, Abbott Park, IL, ³Axio Research LLC, Seattle, WA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) is an effective medication in the treatment of rheumatoid arthritis (RA). However, it is not clear whether the use of ADA is associated…
Abstract Number: 380 • 2012 ACR/ARHP Annual Meeting
DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry
John J. Cush¹, George Reed², Katherine C. Saunders³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Arthur Kavanaugh⁶, ¹Baylor Research Institute, Dallas, TX, ²Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ³Corrona, LLC., Southborough, MA, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶UCSD School of Medicine, La Jolla, CA
Background/Purpose: CORRONA is a nationwide longitudinal disease-based registry that includes 32875 rheumatoid (RA) and 5462 psoriatic arthritis (PsA) patients. We sought to ascertain the frequency…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].